Defunct Company
Total Trials
45
As Lead Sponsor
34
As Collaborator
11
Total Enrollment
3,914
NCT00381654
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2006
Completion: Feb 28, 2010
NCT00502307
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Phase: Phase 2
Start: Oct 31, 2007
Completion: Aug 31, 2010
NCT00551850
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
Completion: May 31, 2010
NCT00563147
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Start: Nov 30, 2007
Completion: Feb 28, 2011
NCT00660153
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
Start: Jun 30, 2008
Completion: Jun 30, 2012
NCT00725634
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Start: Sep 30, 2008
Completion: Dec 31, 2013
NCT00826878
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Start: Jan 31, 2009
Completion: May 31, 2011
NCT00717340
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
Start: Feb 28, 2009
NCT00969410
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
Start: Aug 31, 2009
Completion: Mar 31, 2011
NCT01030783
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Phase: Phase 3
Start: Dec 31, 2009
Completion: Jun 30, 2013
NCT01039948
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
Phase: Phase 1/2
Completion: Aug 31, 2013
NCT01058655
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Role: Collaborator
Start: Feb 28, 2010
Completion: Apr 30, 2015
NCT01076010
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
Start: Mar 31, 2010
Completion: Jul 31, 2014
NCT01369433
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Phase: N/A
Start: Jun 30, 2010
Completion: Oct 31, 2015
NCT01210846
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
Start: Oct 31, 2010
Completion: Jul 31, 2011
NCT01306630
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Start: Nov 30, 2010
Completion: Jan 31, 2014
NCT01297244
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Start: Jan 31, 2011
Completion: Oct 31, 2012
NCT01316848
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
Start: Feb 28, 2011
NCT01363778
A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
Start: May 31, 2011
NCT01363804
A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01478594
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Start: Dec 31, 2011
Completion: Jan 31, 2015
NCT01603979
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
Start: May 31, 2012
Completion: Dec 31, 2014
NCT01631097
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01673386
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Start: Jul 31, 2012
NCT01745367
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Start: Nov 30, 2012
Completion: Jun 30, 2014
NCT01782313
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Start: Mar 6, 2013
Completion: Dec 28, 2016
NCT01769885
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Start: Mar 14, 2013
Completion: Dec 2, 2013
NCT01807156
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Start: Mar 31, 2013
Completion: Feb 28, 2015
NCT01835223
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Start: Jul 11, 2013
Completion: Nov 8, 2019
NCT01972516
Tivozanib As Maintenance Therapy In GYN
Start: Nov 30, 2013
Completion: Jan 31, 2016
NCT02318368
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Start: Nov 30, 2014
Completion: Jan 31, 2017
NCT02109627
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Start: May 1, 2015
Completion: Dec 2, 2019
NCT02277197
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Start: Aug 31, 2015
Completion: Feb 28, 2018
NCT02277184
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
Start: Sep 30, 2015
Completion: Sep 30, 2016
NCT02627963
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
Start: May 24, 2016
Completion: Jun 21, 2021
NCT03136627
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
Start: Mar 22, 2017
Completion: Jun 18, 2021
NCT03316599
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Start: Jan 17, 2018
Completion: Jul 29, 2021
NCT03970616
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Start: Sep 30, 2019
Completion: Apr 4, 2023
NCT04100330
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Start: Jan 31, 2020
Completion: Mar 27, 2020
NCT04815551
A Phase 1 Study of AV-380 in Healthy Subjects
Start: Feb 22, 2021
Completion: Jan 14, 2022
NCT04987203
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Start: Sep 9, 2021
Completion: Dec 30, 2025
NCT05865535
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Start: Jun 13, 2023
Completion: Jun 30, 2026
NCT06053658
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Start: Jan 5, 2024
Completion: Nov 1, 2028
NCT06064877
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Start: Jan 11, 2024
Completion: Nov 30, 2027